Jody A. Charnow

Editor https://www.cancertherapyadvisor.com

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

News

Real-World Data Confirm Efficacy of ¹⁷⁷Lutetium PSMA-617 for mCRPC

Jody A. Charnow

August 31, 2023

A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators reported.

Senior woman lying on hospital bed with her doctor standing by using digital tablet.

Renal Cell Carcinoma

Lymphovascular Invasion Ups Mortality Risk in Kidney Cancer Surgery

Jody A. Charnow

August 29, 2023

Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.

Prostate Cancer

Adding Cabazitaxel to AAP Improves Outcomes in mCRPC

Jody A. Charnow

August 23, 2023

Adding cabazitaxel to abiraterone acetate and prednisone improves outcomes in patients with metastatic castration-resistant prostate cancer, a phase 2 study suggests.

Female doctor writing notes while talking to male patient in hospital ward

Prostate Cancer

Hospitalization Risk Higher With Abiraterone Than With Enzalutamide

Jody A. Charnow

July 25, 2023

Investigators reported findings from one of the largest cohorts of patients treated with androgen receptor pathway inhibitors.

Prostate Cancer

Prostate Cancer Active Surveillance Outcomes Unaffected by TRT

Jody A. Charnow

July 21, 2023

In a retrospective study of men on active surveillance for localized prostate cancer, testosterone replacement therapy did not increase the likelihood of converting to treatment.

Shot of a doctor discussing something on a digital tablet with a senior couple in a clinic

ASCO 2023 Genitourinary Cancer In-Depth

ASCO 2023: Improving Genitourinary Cancer Care

Jody A. Charnow

June 29, 2023

At ASCO 2023, investigators reported results from phase 3 trials that could improve therapeutic approaches to bladder, prostate, and kidney cancer.

ASCO 2023

Erdafitinib Plus Cetrelimab Elicits Durable Responses in Metastatic Urothelial Carcinoma

Jody A. Charnow

June 16, 2023

Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.

ASCO 2023

Add-On Prostate Radiotherapy for De Novo Low-Volume mCSPC Improves Outcomes

Jody A. Charnow

June 8, 2023

Prostate radiotherapy added to intensified systemic therapy for de novo low-volume mCSPC decreases the risk of radiographic disease progression.

ASCO 2023

Immune Checkpoint Inhibitor Rechallenge of No Benefit in Advanced RCC

Jody A. Charnow

June 6, 2023

Immune checkpoint inhibitor rechallenge did not improve outcomes in patients with advanced renal cell carcinoma in the phase 3 CONTACT-03 trial.

ASCO 2023

Erdafitinib Bests Chemotherapy in FGFR-Altered Metastatic Urothelial Carcinoma

Jody A. Charnow

June 6, 2023

Erdafitinib improves survival vs chemotherapy in patients with metastatic urothelial carcinoma and select FGFR alterations who were previously treated with immune checkpoint inhibitors, a phase 3 trial suggests.

Next post in ASCO 2023